Glympse Bio Overview
- Year Founded
-
2015
- Status
-
Acquired/Merged
- Employees
-
16
- Latest Deal Type
-
M&A
- Latest Deal Amount
-
$23.2M
Glympse Bio General Information
Description
Operator of a diagnostic platform intended to facilitate noninvasive disease monitoring through bio-marker technology. The company's platform utilizes precisely engineered diagnostic agents that interrogate the body for certain disease states and then carry the message to the urine for analysis, enabling physicians to use noninvasive and predictive monitoring of multiple human diseases like certain cancers, blood-clotting diseases, and fibrosis of the liver accurately.
Contact Information
Website
www.glympsebio.comCorporate Office
- 35 Cambridgepark Drive
- Suite 100
- Cambridge, MA 02140
- United States
Corporate Office
- 35 Cambridgepark Drive
- Suite 100
- Cambridge, MA 02140
- United States
Glympse Bio Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 7. Merger/Acquisition | 09-Aug-2023 | $23.2M | Completed | Generating Revenue | ||
| 6. Later Stage VC (Series B) | 17-Dec-2021 | Completed | Pre-Clinical Trials | |||
| 5. Later Stage VC (Series B) | 15-Jul-2020 | Completed | Pre-Clinical Trials | |||
| 4. Grant | 01-Jun-2019 | Completed | Pre-Clinical Trials | |||
| 3. Early Stage VC (Series A) | 06-Aug-2018 | Completed | Pre-Clinical Trials | |||
| 2. Accelerator/Incubator | Completed | Pre-Clinical Trials | ||||
| 1. Grant | 01-Jan-2018 | $781K | Completed | Pre-Clinical Trials |
Glympse Bio Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series B | ||||||||
| Series A2 | ||||||||
| Series A1 | 10,831,564 | $0.000100 | 8% | $2.03 | $2.03 | 1x | $2.03 | 17.91% |
Glympse Bio Comparisons
Industry
Financing
Details
Glympse Bio Competitors (3)
One of Glympse Bio’s 3 competitors is Indi Molecular, a Venture Capital-Backed company based in Los Angeles, CA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Indi Molecular | Venture Capital-Backed | Los Angeles, CA | ||||
| Natus Medical | Private Equity-Backed | Middleton, WI | ||||
| Sense Biodetection | Formerly VC-backed | Abingdon, United Kingdom |
Glympse Bio Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Glympse Bio Patents
Glympse Bio Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2023192417-A2 | Ex vivo protease activity detection for hepatocellular carcinoma | Inactive | 30-Mar-2022 | ||
| WO-2023192417-A3 | Ex vivo protease activity detection for hepatocellular carcinoma | Inactive | 30-Mar-2022 | ||
| WO-2023172648-A2 | Fluorogenic substrates for aminopeptidase detection in biofluids | Inactive | 09-Mar-2022 | ||
| WO-2023172648-A3 | Fluorogenic substrates for aminopeptidase detection in biofluids | Inactive | 09-Mar-2022 | ||
| WO-2023172654-A2 | Method of protease detection | Inactive | 09-Mar-2022 | C12Q1/37 |
Glympse Bio Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Glympse Bio Former Investors (23)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| ARCH Venture Partners | Venture Capital | Minority | ||
| Alumni Ventures | Venture Capital | Minority | ||
| Angel (individual) | Minority | |||
| Ascan Investments | Family Office | Minority | ||
| Aspect Ventures | Venture Capital | Minority |
Glympse Bio FAQs
-
When was Glympse Bio founded?
Glympse Bio was founded in 2015.
-
Where is Glympse Bio headquartered?
Glympse Bio is headquartered in Cambridge, MA.
-
What is the size of Glympse Bio?
Glympse Bio has 16 total employees.
-
What industry is Glympse Bio in?
Glympse Bio’s primary industry is Drug Discovery.
-
Is Glympse Bio a private or public company?
Glympse Bio is a Private company.
-
What is the current valuation of Glympse Bio?
The current valuation of Glympse Bio is .
-
What is Glympse Bio’s current revenue?
The current revenue for Glympse Bio is .
-
How much funding has Glympse Bio raised over time?
Glympse Bio has raised $90.8M.
-
Who are Glympse Bio’s investors?
ARCH Venture Partners, Alumni Ventures, , Ascan Investments, and Aspect Ventures are 5 of 23 investors who have invested in Glympse Bio.
-
Who are Glympse Bio’s competitors?
Indi Molecular, Natus Medical, and Sense Biodetection are competitors of Glympse Bio.
-
When was Glympse Bio acquired?
Glympse Bio was acquired on 09-Aug-2023.
-
Who acquired Glympse Bio?
Glympse Bio was acquired by Sunbird Bio.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
